Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Use este enlace para citarhttp://hdl.handle.net/2183/18373
MetadatosMostrar el registro completo del ítem
TítuloLong-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors
Pernas B, Grandal M, Tabernilla A, et al. Long-term clinical experience with darunavir (2007–2015) in a large cohort of HIV-infected patients in Spain authors. J Med Vir. 2016;88(12):2125-31
[Abstract] The clinical experience with the protease inhibitor darunavir/ritonavir (DRV/r) was retrospectively evaluated in a cohort of 173 HIV+ patients who initiated antiretroviral treatment including DRV/r (period 2007–2015). The 43.2% had a CD4 nadir ≤100 cells/mm3, 64.1% were treatment-experienced, and 36.5% had failed to >3 lines of antiretroviral therapy. Nonetheless, the rate of virological suppression (HIV-RNA <50 copies/ml) in naïve patients was 63%, 66.7%, and 63.6% at 48, 96, and 144 weeks, respectively. The rate of virological suppression in treatment-experienced patients was 62.7%, 78.7%, and 79.1% at 48, 96, and 144 weeks, respectively. No differences were observed according to the immunovirological status neither dosage of DRV/r. Most of them (82.6%) maintained DRV/r treatment. Causes for DRV/r discontinuation were mainly gastrointestinal and cutaneous adverse events (10.5%), switch to simplification treatment strategies (3.5%) and virological failure (1.7%). These findings demonstrate the prolonged efficacy and tolerability of DRV/r even in multi-treated HIV+ patients with an unfavorable immunovirological status.
Versión del editor
This is the peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving